Creating new antibodies to treat Alzheimer's disease
Official title: Developing therapeutic antibodies for Alzheimer's disease
Funded at Versapeutics INC · NIH-10821560 · Data updated 2026-11-12
This study is exploring new antibody treatments for Alzheimer's disease, hoping to find better ways to slow down its progression, and patients may get a chance to be part of future trials that could lead to new options for managing the condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versapeutics INC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $489,628 |
| NIH project number | 1R43AG085809-01 |
| Project ID | NIH-10821560 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with Alzheimer's disease.
✕Less likely to help
Patients with other forms of dementia or cognitive impairment unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on developing innovative therapeutic antibodies aimed at treating Alzheimer's disease, a condition that currently lacks effective therapies to slow its progression. The project involves conducting preclinical studies to evaluate the pharmacokinetics and pharmacology of these novel drug candidates. By understanding how these antibodies interact within the body, the research aims to lay the groundwork for future clinical trials. Patients may have the opportunity to participate in studies that could lead to new treatment options for Alzheimer's.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly slow the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in developing therapeutic antibodies for neurodegenerative diseases, indicating potential for success in this area.
Where this research is happening
-
Versapeutics INC
San Diego, United States Active
Researchers
- Principal investigator: Sun, Miao — Versapeutics INC
- Study coordinator: Sun, Miao
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.